Xeris Biopharma Holdings, Inc. (XERS)

Xeris Biopharma Holdings Statistics

Total Valuation

XERS has a market cap or net worth of $559.06 million. The enterprise value is $760.62 million.

Market Cap	559.06M
Enterprise Value	760.62M

Important Dates

The next estimated earnings date is Wednesday, March 5, 2025, before market open.

Earnings Date	Mar 5, 2025
Ex-Dividend Date	n/a

Share Statistics

XERS has 149.08 million shares outstanding. The number of shares has increased by 5.01% in one year.

Current Share Class	149.08M
Shares Outstanding	149.08M
Shares Change (YoY)	+5.01%
Shares Change (QoQ)	+0.44%
Owned by Insiders (%)	4.91%
Owned by Institutions (%)	45.00%
Float	141.77M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.88
Forward PS	2.33
PB Ratio	-19.74
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	4.06
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.79

Current Ratio	1.79
Quick Ratio	1.21
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-1.52

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-8.70%
Return on Invested Capital (ROIC)	-11.90%
Return on Capital Employed (ROCE)	-19.63%
Revenue Per Employee	$496,979
Profits Per Employee	-$167,408
Employee Count	377
Asset Turnover	0.58
Inventory Turnover	0.84

Taxes

Income Tax	-2.50M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +18.67% in the last 52 weeks. The beta is 1.23, so XERS's price volatility has been higher than the market average.

Beta (5Y)	1.23
52-Week Price Change	+18.67%
50-Day Moving Average	3.49
200-Day Moving Average	2.85
Relative Strength Index (RSI)	57.32
Average Volume (20 Days)	1,849,293

Short Selling Information

The latest short interest is 10.49 million, so 7.03% of the outstanding shares have been sold short.

Short Interest	10.49M
Short Previous Month	10.36M
Short % of Shares Out	7.03%
Short % of Float	7.40%
Short Ratio (days to cover)	7.03

Income Statement

In the last 12 months, XERS had revenue of $187.36 million and -$63.11 million in losses. Loss per share was -$0.44.

Revenue	187.36M
Gross Profit	152.44M
Operating Income	-45.17M
Pretax Income	-59.08M
Net Income	-63.11M
EBITDA	-33.06M
EBIT	-45.17M
Loss Per Share	-$0.44

Balance Sheet

The company has $69.40 million in cash and $270.97 million in debt, giving a net cash position of -$201.56 million or -$1.35 per share.

Cash & Cash Equivalents	69.40M
Total Debt	270.97M
Net Cash	-201.56M
Net Cash Per Share	-$1.35
Equity (Book Value)	-28.32M
Book Value Per Share	-0.19
Working Capital	71.79M

Cash Flow

In the last 12 months, operating cash flow was -$31.49 million and capital expenditures -$780,000, giving a free cash flow of -$32.27 million.

Operating Cash Flow	-31.49M
Capital Expenditures	-780,000
Free Cash Flow	-32.27M
FCF Per Share	-$0.22

Margins

Gross margin is 81.36%, with operating and profit margins of -24.11% and -33.69%.

Gross Margin	81.36%
Operating Margin	-24.11%
Pretax Margin	-35.02%
Profit Margin	-33.69%
EBITDA Margin	-17.65%
EBIT Margin	-24.11%
FCF Margin	n/a

Dividends & Yields

XERS does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-5.01%
Shareholder Yield	-5.01%
Earnings Yield	-11.29%
FCF Yield	-5.77%

Analyst Forecast

The average price target for XERS is $5.15, which is 37.33% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$5.15
Price Target Difference	37.33%
Analyst Consensus	Strong Buy
Analyst Count	4
Revenue Growth Forecast (5Y)	16.78%
EPS Growth Forecast (5Y)	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

XERS has an Altman Z-Score of -1.97 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.97
Piotroski F-Score	2